Interleukin 2 receptors (IL-2R) are cytokine receptors that are expressed on regulatory T cells (Tregs), CD8+ T cells, and natural killer cells. IL-2Rα is commonly found on Tregs, and when activated by its ligand IL-2, it contributes to Treg development, activity, and survival.1
Tregs constitute 5%-10% of circulating CD4+ T cells.2 In normal tissue, Tregs suppress T cells and control both innate and adaptive immune responses.2,3 Deficiency or damage to Tregs—such as after a hematopoietic stem cell transplant—may lead to autoimmunity and chronic graft versus host disease.4
Activation of IL-2Rα may increase Treg production to help manage inflammatory diseases.
Learn more about modalities targeting IL-2Rα:
Search our clinical trials.
CD: cluster of differentiation.
1. Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015;36(12):763-777. 2. Piccirillo CA, Shevach EM. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol. 2004;16(2):81-88. 3. Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F. CD4+CD25+ TR cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med. 2003;197(1):111-119. 4. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absesce of regulatory T-cell control TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft versus-host disease. Blood. 2007;110(10):3804-3813.